

BIOCRYST PHARMACEUTICALS INC
 Form 4
 February 14, 2006

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 FEATHERINGILL WILLIAM W

2. Issuer Name and Ticker or Trading Symbol
 BIOCRYST PHARMACEUTICALS INC [BCRX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

Director 10% Owner
 Officer (give title below) Other (specify below)

2190 PARKWAY LAKE DRIVE

02/10/2006
 4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(Street)

BIRMINGHAM, AL 35244-

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock				(A) or (D)	Price		
				Code V	Amount		
Common Stock	02/10/2006		S	1,700	D \$ 16.2	939,500	I Featheringill Family Partnership II, L.P. ⁽¹⁾
Common Stock	02/10/2006		S	1,400	D \$ 16.335	938,100	I Featheringill Family Partnership II, L.P. ⁽¹⁾
	02/10/2006		S	829	D \$ 16.5	937,271	I

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock								Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	771	D	\$ 16.5052	936,500	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	1,050	D	\$ 16.51	935,450	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	1,900	D	\$ 16.52	933,550	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	200	D	\$ 16.525	933,350	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	200	D	\$ 16.53	933,150	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	550	D	\$ 16.5355	932,600	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	2,800	D	\$ 16.54	929,800	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	2,600	D	\$ 16.55	927,200	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	100	D	\$ 16.56	927,100	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
Common Stock	02/10/2006	S	15	D	\$ 16.57	927,085	I	Featheringill Family Partnership II, L.P. <u>(1)</u>
	02/10/2006	S	385	D	\$ 16.577	926,700	I	

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock									Featheringill Family Partnership II, L.P. ⁽¹⁾
Common Stock	02/10/2006	S	200	D	\$ 16.58	926,500	I		Featheringill Family Partnership II, L.P. ⁽¹⁾
Common Stock	02/10/2006	S	347	D	\$ 16.59	926,153	I		Featheringill Family Partnership II, L.P. ⁽¹⁾
Common Stock	02/10/2006	S	953	D	\$ 16.612	925,200	I		Featheringill Family Partnership II, L.P. ⁽¹⁾
Common Stock	02/10/2006	S	200	D	\$ 16.62	925,000	I		Featheringill Family Partnership II, L.P. ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6)
				Code V (A) (D)		Date Exercisable Expiration Date	Title Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FEATHERINGILL WILLIAM W 2190 PARKWAY LAKE DRIVE BIRMINGHAM, AL 35244-			X	

Signatures

Michael
Richardson 02/14/2006

__Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Mr. Featheringill is sole manager, with investment and voting power, and a general partner.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.